Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma
1996

Monitoring Treatment Response in Bone Metastases from Breast Cancer

Sample size: 36 publication Evidence: moderate

Author Information

Author(s): C Blomqvist, L Risteli, J Risteli, P Virkkunen, S Sarna, I Elomaa

Primary Institution: University of Helsinki

Hypothesis

Can biochemical markers of type I collagen metabolism effectively monitor treatment response in patients with bone metastases from breast carcinoma?

Conclusion

Changes in the levels of collagen metabolites ICTP and PICP correlate with treatment response in patients with bone metastases from breast cancer.

Supporting Evidence

  • Reduction in ICTP correlated significantly with treatment response at three months.
  • PICP and ICTP changes differed significantly between patients with progressive disease and those with responding or stable metastases.
  • Both ICTP and PICP showed statistically significant correlations to other markers of bone metabolism.

Takeaway

Doctors can check certain proteins in the blood to see how well treatment is working for breast cancer that has spread to the bones.

Methodology

Patients were monitored for treatment response using biochemical markers of bone metabolism and conventional radiography.

Limitations

The study only monitored biochemical markers during a 3-month period, which may not reflect early treatment responses.

Participant Demographics

Fifty normocalcaemic female patients with painful bone metastases from breast cancer.

Statistical Information

P-Value

P<0.0005 for ICTP change and treatment response; P=0.03 for PICP change and treatment response.

Confidence Interval

95% CI 0.22-0.72 for ICTP; 95% CI 0.26-0.74 for PICP.

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication